(NASDAQ: CRVO) Cervomed's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.15%.
Cervomed's earnings in 2026 is -$30,349,743.On average, 9 Wall Street analysts forecast CRVO's earnings for 2026 to be -$41,439,930, with the lowest CRVO earnings forecast at -$64,304,539, and the highest CRVO earnings forecast at -$27,781,339. On average, 8 Wall Street analysts forecast CRVO's earnings for 2027 to be -$36,626,010, with the lowest CRVO earnings forecast at -$68,156,885, and the highest CRVO earnings forecast at -$21,590,069.
In 2028, CRVO is forecast to generate -$35,880,639 in earnings, with the lowest earnings forecast at -$50,524,995 and the highest earnings forecast at -$19,208,811.